Regulatory tracker: Europe serves up earlier lymphoma nod for Roche's Columvi as final review of Eisai's Leqembi kicks off
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
